279 related articles for article (PubMed ID: 12183423)
1. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
[TBL] [Abstract][Full Text] [Related]
2. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.
Banerjee NS; Rivera AA; Wang M; Chow LT; Broker TR; Curiel DT; Nettelbeck DM
Mol Cancer Ther; 2004 Apr; 3(4):437-49. PubMed ID: 15078987
[TBL] [Abstract][Full Text] [Related]
3. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.
Rivera AA; Davydova J; Schierer S; Wang M; Krasnykh V; Yamamoto M; Curiel DT; Nettelbeck DM
Gene Ther; 2004 Dec; 11(23):1694-702. PubMed ID: 15496964
[TBL] [Abstract][Full Text] [Related]
4. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
5. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
6. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
7. A novel attenuated replication-competent adenovirus for melanoma therapy.
Peter I; Graf C; Dummer R; Schaffner W; Greber UF; Hemmi S
Gene Ther; 2003 Apr; 10(7):530-9. PubMed ID: 12646858
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
10. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.
Hoffmann D; Jogler C; Wildner O
J Gene Med; 2005 Oct; 7(10):1356-66. PubMed ID: 15945123
[TBL] [Abstract][Full Text] [Related]
12. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
Bilsland AE; Merron A; Vassaux G; Keith WN
Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
[TBL] [Abstract][Full Text] [Related]
13. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.
Fechner H; Wang X; Picó AH; Wildner J; Suckau L; Pinkert S; Sipo I; Weger S; Poller W
J Biotechnol; 2007 Jan; 127(4):560-74. PubMed ID: 17083991
[TBL] [Abstract][Full Text] [Related]
14. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells.
Zheng X; Rao XM; Snodgrass CL; McMasters KM; Zhou HS
Cancer Gene Ther; 2006 Jun; 13(6):572-83. PubMed ID: 16341141
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
16. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
17. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.
Hurtado Picó A; Wang X; Sipo I; Siemetzki U; Eberle J; Poller W; Fechner H
Mol Ther; 2005 Apr; 11(4):563-77. PubMed ID: 15771959
[TBL] [Abstract][Full Text] [Related]
18. [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma].
Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Xu JM; Qian YZ; Qian QJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):468-72. PubMed ID: 15854553
[TBL] [Abstract][Full Text] [Related]
19. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses.
Schmitz M; Graf C; Gut T; Sirena D; Peter I; Dummer R; Greber UF; Hemmi S
Gene Ther; 2006 Jun; 13(11):893-905. PubMed ID: 16482201
[TBL] [Abstract][Full Text] [Related]
20. Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system.
Nagayama Y; Nishihara E; Namba H; Yokoi H; Hasegawa M; Mizuguchi H; Hayakawa T; Hamada H; Yamashita S; Niwa M
Cancer Gene Ther; 2001 Jan; 8(1):36-44. PubMed ID: 11219492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
